Disease Control on Lanreotide Autogel ® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report

We report a disease control on a long-acting SSA lanreotide in a patient with metastatic gastrinoma. A 60-year-old man, who had previously undergone a surgical resection of metastatic pancreatic gastrinoma, presented with abdominal bloating, edema in the lower limbs, fatigue, and weight loss. The gastrinoma relapse with additional metastases in the pancreas, duodenum, and liver was confirmed by positron emission tomography-computed tomography (PET-CT) scan; the patient ’s blood gastrin level was #x3e;5,000 ng/L. Treatment with the SSA octreotide long-acting release was initiated to treat the gastrinoma relapse. On the CT scan done in September 2011, the liver metastases were still identifiable. In December 2011, the treatment was switched to lanreotide Autogel® (120 mg every 2 weeks). Following the treatment, the gastrin levels were reduced to #x3c;1,200 ng/L in September 2013, and 812 ng/L in July 2016. Since November 2012, the gastrinoma lesions were no longer visible in abdominal CT. At the time of this report, the patient’s gastrinoma was under cont rol with lanreotide Autogel®. This case report supports the use of lanreotide Autogel® as effective treatment for metastatic gastrinoma.Case Rep Gastroenterol 2017;11:616 –623
Source: Case Reports in Gastroenterology - Category: Gastroenterology Source Type: research

Related Links:

CONCLUSIONS: Internal target motion may differ from external surrogate motion in DIBH treatment. Radiographic verification of target position at the beginning and during each fraction is necessary for precise RT delivery. IMR can serve as a useful tool to directly monitor the internal target motion. PMID: 30933428 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
By HANS DUVEFELT MD Jeanette Brown had lost twenty pounds, and she was worried. “I’m not trying,” she told me at her regular diabetes visit as I pored over her lab results. What I saw sent a chill down my spine: A normal weight, diet controlled diabetic for many years, her glycosylated hemoglobin had jumped from 6.9 to 9.3 in three months while losing that much weight. That is exactly what happened to my mother some years ago, before she was diagnosed with the pancreatic cancer that took her life in less than two years. Jeanette had a normal physical exam and all her bloodwork except for t...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Medicare Hans Duvefelt Managed Care Source Type: blogs
Authors: Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE Abstract Prostate cancer (PCa) is the most common solid cancer affecting men worldwide. Serum prostate-specific antigen (PSA) is at present the most commonly used biomarker for PCa screening, as well as a reliable marker of disease recurrence after initial treatment. Bone metastases (BM) are present in advanced stages of the disease. Imaging of BM is important not only for localization and characterization, but also to evaluate their size and number, as well as to follow-up the disease during and after therapy. Bone metastases format...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
Objective: The aim of this study was to determine (1) whether preoperative factors can predict resectability of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant FOLFIRINOX, (2) which patients might benefit from adjuvant therapy, and (3) survival differences between resected BR/LA patients who received neoadjuvant FOLFIRINOX and upfront resected patients. Background: Patients with BR/LA PDAC are often treated with FOLFIRINOX to obtain a margin-negative resection, yet selection of patients for resection remains challenging. Methods: Clinicopathologic data ...
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research
AbstractBackgroundImmunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imaging, and many have unusual immune-related adverse events that cannot be predicted in advance. In this exploratory study, we investigate how 3 ′-Deoxy-3’-18F-fluorothymidine (FLT) positron emission tomography (PET) measurements of tumor and immune cell proliferation might be utilized as biomarkers in immunotherapy.MethodsSeventeen patients with metastatic castrate resistant prostate cancer...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
AbstractPurposeWe assessed differences in gross tumor volumes (GTVs) for pancreatic cancer between respiratory-ungated positron emission tomography (3D-PET) and contrast-enhanced four-dimensional computed tomography (CE-4DCT).Materials and methodsWe evaluated the GTVs in 21 patients. The sum of the GTVs, which was individually delineated by observers 1 and 2 on the CE-4DCT images from all respiratory phases, was used as GTV-4DCT. The GTVs on the 3D-PET images were extracted with three thresholds: 20%, 30%, and 40% of maximum activity concentration (GTV-n%). We selected one of the GTV-n%, which mostly resembled GTV-4DCT in ...
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
entini V, Morganti AG, Genovesi D Abstract BACKGROUND: Due to the high soft tissue resolution, magnetic resonance imaging (MRI) could improve the accuracy of pancreatic tumor delineation in radiation treatment planning. A multi-institutional study was proposed to evaluate the impact of MRI on inter-observer agreement in gross tumor volume (GTV) and duodenum delineation for pancreatic cancer compared with computer tomography (CT). MATERIAL AND METHODS: Two clinical cases of borderline resectable (Case 1) and unresectable (Case 2) pancreatic cancer were selected. In two sequential steps, diagnostic contrast-enh...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
ConclusionFSPG PET is superior to FDG PET in detecting metastasized PDAC, especially in the liver.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
CONCLUSIONS:: 125I implantation could effectively relieve the pain in the patients with advanced primary or metastatic retroperitoneal malignant tumors and suppress local tumor progress. PMID: 30803402 [PubMed - in process]
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Tags: Technol Cancer Res Treat Source Type: research
CONCLUSION:: The proposed radiomics-based computer-aided diagnosis scheme could increase preoperative diagnostic accuracy and assist clinicians in making accurate management decisions. PMID: 30803366 [PubMed - in process]
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Tags: Technol Cancer Res Treat Source Type: research
More News: Brain | Cancer | Cancer & Oncology | CT Scan | Gastroenterology | Liver | Neurology | Pancreas | Pancreatic Cancer | PET Scan | Study | Urology & Nephrology | Weight Loss